Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

The model was associated with a mild trend for reduced plasma myostatin (Figure 3b ), increased plasma activin A (NTB: 0.10 ± 0.01 ng/mL; tumour: 0.30 ± 0.05 ng/mL; p < 0.05), significant progressive body weight loss ( p < 0.0001; Figure 3c ) that included lean, fat and hindlimb muscle mass ( p < 0.01; Figure 3d,e ).

also in 257 other papers

In the TOV21G model, combining anti‐myostatin and anti‐GDF‐15 antibodies led to even greater increases in body weight and hindlimb muscle mass compared with anti‐GDF‐15 antibody alone ( p < 0.001 for muscle mass); however, the increase in muscle strength and treadmill running did not reach statistical significance over monotherapy.

also in 111,027 other papers